The @US_FDA has approved #Leqembi treatment for maintenance dosing, enabling patients to switch to once-monthly treatment after 18-months of biweekly treatment.#lecanemab @AlzAssociation @EisaiUS @biogen @bioarcticab @AANmember @ACPIMphysicians